Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators

Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators Publisher

Kordzadehkermani E¹ ; Khalili H¹ ; Karimzadeh I² ; Salehi M³

Show Affiliations

1. Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Infectious Diseases, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Infection and Drug Resistance Published:2020

Abstract

The introduction of biologic and targeted immunomodulators is a significant breakthrough in the therapeutic area of various fields of medicine. The occurrence of serious infections, a complication of secondary immunosuppression associated with these agents, leads to increased morbidity and mortality. Implementing preventive strategies could minimize infection-related complications and improve therapeutic outcomes. The purpose of this review is to focus on current evident approaches regarding screening, monitoring, preventing (immunization and chemoprophylaxis), and management of infections in patients who are candidates for about 70 biologic and targeted immunomodulators. Recommendations are based on relevant guidelines, especially the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document series published in 2018. © 2020 Kordzadeh-Kermani et al.

2. 2018 Aplar Axial Spondyloarthritis Treatment Recommendations, International Journal of Rheumatic Diseases (2019)

3. Management of Drug-Induced Neutropenia, Thrombocytopenia, and Anaemia After Solid Organ Transplantation: A Comprehensive Review, Journal of Clinical Pharmacy and Therapeutics (2022)

4. Janus-Kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature, Journal of Pediatrics Review (2023)

5. Tuberculosis Comorbidity With Rheumatoid Arthritis: Gene Signatures, Associated Biomarkers, and Screening, IUBMB Life (2021)

6. Examining the Immunological Responses to Covid-19 Vaccination in Multiple Myeloma Patients: A Systematic Review and Meta-Analysis, BMC Geriatrics (2024)

7. Strategies Toward Rheumatoid Arthritis Therapy; the Old and the New, Journal of Cellular Physiology (2019)

Experts (# of related papers)

View all Related Experts

Zeinab Aryanian (1)

Zahra Razavi (1)

Style	Citing Format
MLA	Kordzadehkermani E, et al.. "Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators." Infection and Drug Resistance, vol. 13, no. , 2020, pp. 513-532.
APA	Kordzadehkermani E, Khalili H, Karimzadeh I, Salehi M (2020). Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators. Infection and Drug Resistance, 13(), 513-532.
Chicago	Kordzadehkermani E, Khalili H, Karimzadeh I, Salehi M. "Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators." Infection and Drug Resistance 13, no. (2020): 513-532.
Harvard	Kordzadehkermani E et al. (2020) 'Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators', Infection and Drug Resistance, 13(), pp. 513-532.
Vancouver	Kordzadehkermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators. Infection and Drug Resistance. 2020;13():513-532.
BibTex	@article{ author = {Kordzadehkermani E and Khalili H and Karimzadeh I and Salehi M}, title = {Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators}, journal = {Infection and Drug Resistance}, volume = {13}, number = {}, pages = {513-532}, year = {2020} }
RIS	TY - JOUR AU - Kordzadehkermani E AU - Khalili H AU - Karimzadeh I AU - Salehi M TI - Prevention Strategies to Minimize the Infection Risk Associated With Biologic and Targeted Immunomodulators JO - Infection and Drug Resistance VL - 13 IS - SP - 513 EP - 532 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract